Home › Alpha-1 Antitrypsin Deficiency › Ohio
Alpha-1 Antitrypsin Deficiency clinical trials in Ohio
3 studies for Alpha-1 Antitrypsin Deficiency are looking for participants at sites in Ohio.
Cities in Ohio
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Nov 12, 2026 · NCT06165341A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- GC2501 Study Site 104, Cleveland
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Oct 26, 2026 · NCT07555483Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated May 13, 2026 · NCT05677971From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.